Advancing Treatment for Immunological Diseases with Real-World Evidence and Data Analytics

August 16, 2022

Immune-mediated inflammatory diseases (IMIDs) are often difficult and expensive to treat, but new advances are being made with real-world evidence (RWE) and artificial intelligence (AI) by Jannen’s Immunology and R&D Data Science teams. Pulling real-world data (RWD) from a variety of sources, researchers can create phenotypic profiles based on real patients. In addition, RWE and data science allow for more efficient clinical trial design.

According to Hemanth Kanakamedala, senior director, The Janssen Pharmaceutical Companies of Johnson & Johnson, “Knowledge of a disease’s natural history is critical for drug development. We utilize RWD to inform the design of our interventional studies, including inclusion/exclusion criteria, diagnostic criteria, adequate follow-up, assumptions to power the study, and other design components.”

To read more, click here.

(Source: Clinical Leader, August 15th, 2022)

Share This Story!